Pfizer Inc.

Pfizer, DNDi Partner To Identify NTD Drugs; Sanofi-Aventis, Medicines For Malaria Launch Drug Study

Medical News Today (Free subscription) | yesterday

Pfizer and the Drugs for Neglected Diseases Initiative (DNDi) on Wednesday announced plans to team up in an effort to identify new drug candidates for the treatment of three tropical diseases, the Associated Press/Business Week reports. The scientists will test the efficacy of Pfizer drug candidates against sleeping sickness, visceral leishmaniasis, and Chagas disease.

Pfizer - Prempro: Kris Hundley writes

PharmaGossip (Free subscription) | yesterday

Is Prempro, the hormone drug known to increase the risk of breast cancer, a public hazard? If a judge in Pinellas County determines that it is, hundreds of thousands of documents now under seal in lawsuits against the drug's manufacturer nationwide could be released for the public to inspect. The key to the confidential company records has ended up in Pinellas-Pasco Circuit Judge Anthony Rondolino's...

• Secret Prempro Documents To Surface In Florida? - Pharmalot

Pfizer's Geodon gets expanded FDA approval

Seattle Times (Free subscription) | yesterday

Pfizer Inc. said Friday the Food and Drug Administration approved Geodon as a part of a combination maintenance treatment for bipolar disorder in adults.

Pfizer gets FDA approval for intravenous Revatio

Seattle Times (Free subscription) | yesterday

Drug developer Pfizer Inc. said Friday the Food and Drug Administration approved an intravenous version of its high blood pressure drug Revatio.

Pfizer Receives FDA Approval For Geodon® (Ziprasidone HCI) Capsules For The Adjunctive Maintenance Treatment Of Bipolar Disorder In Adults

Business Wire (Free subscription) | yesterday

NEW YORK--(BUSINESS WIRE)--Pfizer today announced that the U.S. Food and Drug Administration (FDA) has approved Geodon® (ziprasidone HCI) Capsules for maintenance treatment of bipolar I disorder as an adjunct to lithium or valproate in adults. The approval is based on clinical data demonstrating that Geodon is an effective and generally well-tolerated adjunctive treatment for long-term symptom...

FDA Approves Intravenous Formulation Of Pfizer’s Revatio® (Sildenafil) For The Treatment Of Pulmonary Arterial Hypertension

The Earth Times Online Newspaper (Free subscription) | yesterday

NEW YORK - Pfizer announced today that the U.S. Food and Drug Administration (FDA) has approved Revatio® (sildenafil) Injection, an intravenous formulation of Revatio. Revatio is the only FDA-approved phosphodiesterase-5 (PDE5) inhibitor available in both tablet and int

FDA Approves Intravenous Formulation Of Pfizer’s Revatio® (Sildenafil) For The Treatment Of Pulmonary Arterial Hypertension

Business Wire (Free subscription) | yesterday

NEW YORK--(BUSINESS WIRE)--Pfizer announced today that the U.S. Food and Drug Administration (FDA) has approved Revatio® (sildenafil) Injection, an intravenous formulation of Revatio. Revatio is the only FDA-approved phosphodiesterase-5 (PDE5) inhibitor available in both tablet and intravenous formulations. Revatio is indicated for the treatment of adult patients with pulmonary arterial hypertension...

Pfizer Wants You To Take Fido To Thanksgiving

Pharmalot (Free subscription) | 20/11/2009

Here’s a cynical way to boost drug sales. In a press release that tugs on your heart strings, Pfizer reminds us that some people feel bad about leaving their dog at home when they go elsewhere for the holidays. And the drugmaker also notes the family dog can offer so much comfort, especially at times [...]

Pfizer Dodges a Bullet

Fool.com (Free subscription) | 19/11/2009

The drugmaker slips through an advisory committee unscathed.

Goldman Sachs Puts Pfizer’s 2012 China Sales At $3 Billion

iStockAnalyst.com (Free subscription) | 19/11/2009

In an investment review of Pfizer, Goldman Sachs said sales in emerging growth markets would become a significant factor in the company’s revenues, a fact that it considers underappreciated by stock market investors. China is the major emerging market for Pfizer. Goldman expects emerging growth markets to produce $3.5 billion of revenue for Pfizer in 2012, and $3 billion of that will come from...

Pfizer's Generic Growth, With a Side of Sashimi

Fool.com (Free subscription) | 19/11/2009

A move into Japan isn't a bad idea, but it isn't going to save the company either.

FDA panel backs stronger benefit claims for inhaler drug Spiriva marketed by Pfizer

Star Tribune (Free subscription) | 19/11/2009

WASHINGTON - Federal health experts on Thursday brushed off lingering safety questions about a popular inhaler drug and suggested it carry bolder benefit claims.The Food and Drug Administration's panel of lung specialists voted 11-1 in favor of new labeling about the benefits of Boehringer Ingelheim's Spiriva Handihaler, which is approved to treat lung disease.The FDA is not required to follow the...

Canada Reviews Pfizer Exec Named To Health Board

Pharmalot (Free subscription) | 19/11/2009

Canada’s Health Committee plans to review the controversial appointment of a Pfizer exec to the board of the Canadian Institutes of Health Research, the government agency that oversees health research in Canada, The Tyee reports. Bernard Prigent, Pfizer Canada’s medical director, was appointed last month to the CIHR’s governing council (see here). Last month, CIHR [...]

Huge drug firms laying off research staff

Government and Taxes (Free subscription) | 2 hours ago

There was this news report last Thursday from Nature magazine. http://www.nature.com/naturejobs/2009/091119/full/nj7271-375e.html Published in Nature 462, 375 (18 November 2009) | 10.1038/nj7271-375e Huge cuts by drug firms R&D closure is the latest in a series of hits to drug companies. Pfizer is closing 35% of its global research and development space, according to a 9 November announcement....

Kelo v. New London, Part II – Eminent domain for Atlantic Yards in New York

No Land Grab (Free subscription) | 10 hours ago

RadioVice This review of the eminent domain case pending with the New York State Court of Appeals includes a mention of the questionable criteria used to declare the area in the proposed Atlantic Yards project footprint as blighted and a contrast with how use of eminent domain worked out in New London. It seems that less than half of the 22 acres of the proposed redevelopment area contain a below...